These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 10654009)
21. Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma. Arun B; Slack R; Gehan E; Spitzer T; Meehan KR Cancer; 1999 Jan; 85(1):93-9. PubMed ID: 9921979 [TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome. Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863 [TBL] [Abstract][Full Text] [Related]
23. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731 [TBL] [Abstract][Full Text] [Related]
24. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
25. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Biron P; Durand M; Roché H; Delozier T; Battista C; Fargeot P; Spaeth D; Bachelot T; Poiget E; Monnot F; Tanguy ML; Curé H Bone Marrow Transplant; 2008 Mar; 41(6):555-62. PubMed ID: 18037940 [TBL] [Abstract][Full Text] [Related]
26. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. Schneeweiss A; Hensel M; Goerner R; Khbeis T; Hohaus S; Egerer G; Solomayer E; Haas R; Grischke EM; Bastert G; Ho AD Stem Cells; 2001; 19(2):151-60. PubMed ID: 11239170 [TBL] [Abstract][Full Text] [Related]
27. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
28. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation. Demirer T; Uysal VA; Ayli M; Genc Y; Ilhan O; Koc H; Dagli M; Arat M; Gunel N; Fen T; Dincer S; Ustael N; Yildiz M; Ustun T; Seyrek E; Ozet G; Muftuoglu O; Akan H Bone Marrow Transplant; 2003 May; 31(9):755-61. PubMed ID: 12732881 [TBL] [Abstract][Full Text] [Related]
29. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Vahdat LT; Cohen DJ; Zipin D; Lo KS; Donovan D; Savage D; Tiersten A; Nichols G; Troxel A; Hesdorffer CS Bone Marrow Transplant; 2007 Aug; 40(3):267-72. PubMed ID: 17563739 [TBL] [Abstract][Full Text] [Related]
30. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support. Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326 [TBL] [Abstract][Full Text] [Related]
31. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
32. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: immunologic consequences affecting clinical outcome. Chakraborty N; Bilgrami S; Maness L; Guo C; Perez-Diez A; Mukherji B; Tutschka P Bone Marrow Transplant; 1999 Oct; 24(8):837-43. PubMed ID: 10516693 [TBL] [Abstract][Full Text] [Related]
33. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076 [TBL] [Abstract][Full Text] [Related]
34. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406 [TBL] [Abstract][Full Text] [Related]
35. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Vaughan WP; Reed EC; Edwards B; Kessinger A Bone Marrow Transplant; 1994 May; 13(5):619-24. PubMed ID: 7914447 [TBL] [Abstract][Full Text] [Related]
36. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer. Meehan KR; Arun B; Gehan EA; Berberian B; Sulica V; Areman EM; Mazumder A; Lippman ME Bone Marrow Transplant; 1999 Apr; 23(7):667-73. PubMed ID: 10218842 [TBL] [Abstract][Full Text] [Related]
37. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Weaver CH; West WH; Schwartzberg LS; Alberico T; Leff R; Greco FA; Hainsworth J; Birch R; McAneny B; Magee M; Raefsky E; Kalman L; Buckner CD Bone Marrow Transplant; 1997 Apr; 19(7):661-70. PubMed ID: 9156242 [TBL] [Abstract][Full Text] [Related]
38. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253 [TBL] [Abstract][Full Text] [Related]
39. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284 [TBL] [Abstract][Full Text] [Related]
40. High-dose chemotherapy with peripheral blood stem cell support for stage IIIB inflammatory carcinoma of the breast. Schwartzberg L; Weaver C; Lewkow L; McAneny B; Zhen B; Birch R; West W; Tauer K; Buckner C Bone Marrow Transplant; 1999 Nov; 24(9):981-7. PubMed ID: 10556957 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]